168 related articles for article (PubMed ID: 36134018)
1. Clinical outcomes of dose-escalated re-irradiation in patients with recurrent high-grade glioma.
Helis CA; Prim SN; Cramer CK; Strowd R; Lesser GJ; White JJ; Tatter SB; Laxton AW; Whitlow C; Lo HW; Debinski W; Ververs JD; Black PJ; Chan MD
Neurooncol Pract; 2022 Oct; 9(5):390-401. PubMed ID: 36134018
[TBL] [Abstract][Full Text] [Related]
2. Bevacizumab and re-irradiation for recurrent high grade gliomas: does sequence matter?
Palmer JD; Bhamidipati D; Song A; Eldredge-Hindy HB; Siglin J; Dan TD; Champ CE; Zhang I; Bar-Ad V; Kim L; Glass J; Evans JJ; Andrews DW; Werner-Wasik M; Shi W
J Neurooncol; 2018 Dec; 140(3):623-628. PubMed ID: 30182159
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of salvage fractionated re-irradiation combined with bevacizumab for recurrent high-grade gliomas that progressed after bevacizumab treatment*.
Yonezawa H; Ohno M; Igaki H; Miyakita Y; Takahashi M; Tamura Y; Shima S; Matsushita Y; Ichimura K; Narita Y
Jpn J Clin Oncol; 2021 Jul; 51(7):1028-1035. PubMed ID: 33959771
[TBL] [Abstract][Full Text] [Related]
4. Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone.
Arvold ND; Shi DD; Aizer AA; Norden AD; Reardon DA; Lee EQ; Nayak L; Dunn IF; Golby AJ; Johnson MD; Claus EB; Chiocca EA; Ligon KL; Wen PY; Alexander BM
J Neurooncol; 2017 Dec; 135(3):581-591. PubMed ID: 28975467
[TBL] [Abstract][Full Text] [Related]
5. Re-irradiation for recurrent high-grade glioma: an analysis of prognostic factors for survival and predictors of radiation necrosis.
Moore-Palhares D; Chen H; Keith J; Wang M; Myrehaug S; Tseng CL; Detsky J; Perry J; Lim-Fat MJ; Heyn C; Maralani P; Lipsman N; Das S; Sahgal A; Soliman H
J Neurooncol; 2023 Jul; 163(3):541-551. PubMed ID: 37256526
[TBL] [Abstract][Full Text] [Related]
6. Reirradiation with concurrent bevacizumab for recurrent high-grade gliomas in adult patients.
Schernberg A; Dhermain F; Ammari S; Dumont SN; Domont J; Patrikidou A; Pallud J; Dezamis É; Deutsch É; Louvel G
Cancer Radiother; 2018 Feb; 22(1):9-16. PubMed ID: 29217134
[TBL] [Abstract][Full Text] [Related]
7. A multi-center prospective study of re-irradiation with bevacizumab and temozolomide in patients with bevacizumab refractory recurrent high-grade gliomas.
Dixit KS; Sachdev S; Amidei C; Kumthekar P; Kruser TJ; Gondi V; Grimm S; Lukas RV; Nicholas MK; Chmura SJ; Fought AJ; Mehta M; Raizer JJ
J Neurooncol; 2021 Dec; 155(3):297-306. PubMed ID: 34689306
[TBL] [Abstract][Full Text] [Related]
8. Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Shi W; Blomain ES; Siglin J; Palmer JD; Dan T; Wang Y; Werner-Wasik M; Glass J; Kim L; Bar Ad V; Bhamidipati D; Evans JJ; Judy K; Farrell CJ; Andrews DW
J Neurooncol; 2018 Mar; 137(1):171-177. PubMed ID: 29235052
[TBL] [Abstract][Full Text] [Related]
9. A Retrospective Review of Re-irradiating Patients' Recurrent High-grade Gliomas.
Klobukowski L; Falkov A; Chelimo C; Fogh SE
Clin Oncol (R Coll Radiol); 2018 Sep; 30(9):563-570. PubMed ID: 29891395
[TBL] [Abstract][Full Text] [Related]
10. Re-irradiation and bevacizumab in recurrent high-grade glioma: an effective treatment option.
Flieger M; Ganswindt U; Schwarz SB; Kreth FW; Tonn JC; la Fougère C; Ertl L; Linn J; Herrlinger U; Belka C; Niyazi M
J Neurooncol; 2014 Apr; 117(2):337-45. PubMed ID: 24504501
[TBL] [Abstract][Full Text] [Related]
11. Timing of re-irradiation in recurrent high-grade gliomas: a single institution study.
Zemlin A; Märtens B; Wiese B; Merten R; Steinmann D
J Neurooncol; 2018 Jul; 138(3):571-579. PubMed ID: 29520609
[TBL] [Abstract][Full Text] [Related]
12. Re-irradiation with and without bevacizumab as salvage therapy for recurrent or progressive high-grade gliomas.
Hundsberger T; Brügge D; Putora PM; Weder P; Weber J; Plasswilm L
J Neurooncol; 2013 Mar; 112(1):133-9. PubMed ID: 23314822
[TBL] [Abstract][Full Text] [Related]
13. Bevacizumab in recurrent high-grade glioma: a single institution retrospective analysis on 92 patients.
Detti B; Scoccianti S; Teriaca MA; Maragna V; Lorenzetti V; Lucidi S; Bellini C; Greto D; Desideri I; Livi L
Radiol Med; 2021 Sep; 126(9):1249-1254. PubMed ID: 34081269
[TBL] [Abstract][Full Text] [Related]
14. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
[TBL] [Abstract][Full Text] [Related]
15. Re-resection for recurrent high-grade glioma in the setting of re-irradiation: more is not always better.
Palmer JD; Siglin J; Yamoah K; Dan T; Champ CE; Bar-Ad V; Werner-Wasik M; Evans JJ; Kim L; Glass J; Farrell C; Andrews DW; Shi W
J Neurooncol; 2015 Sep; 124(2):215-21. PubMed ID: 26024653
[TBL] [Abstract][Full Text] [Related]
16. High-dose salvage re-irradiation for recurrent/progressive adult diffuse glioma: healing or hurting?
Gupta T; Maitre M; Maitre P; Goda JS; Krishnatry R; Chatterjee A; Moiyadi A; Shetty P; Epari S; Sahay A; Patil V; Jalali R
Clin Transl Oncol; 2021 Jul; 23(7):1358-1367. PubMed ID: 33528810
[TBL] [Abstract][Full Text] [Related]
17. Cs-131 brachytherapy for patients with recurrent glioblastoma combined with bevacizumab avoids radiation necrosis while maintaining local control.
Wernicke AG; Taube S; Smith AW; Herskovic A; Parashar B; Schwartz TH
Brachytherapy; 2020; 19(5):705-712. PubMed ID: 32928486
[TBL] [Abstract][Full Text] [Related]
18. Multicenter, Phase 1, Dose Escalation Study of Hypofractionated Stereotactic Radiation Therapy With Bevacizumab for Recurrent Glioblastoma and Anaplastic Astrocytoma.
Clarke J; Neil E; Terziev R; Gutin P; Barani I; Kaley T; Lassman AB; Chan TA; Yamada J; DeAngelis L; Ballangrud A; Young R; Panageas KS; Beal K; Omuro A
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):797-804. PubMed ID: 28870792
[TBL] [Abstract][Full Text] [Related]
19. Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma.
Furuse M; Kawabata S; Wanibuchi M; Shiba H; Takeuchi K; Kondo N; Tanaka H; Sakurai Y; Suzuki M; Ono K; Miyatake SI
Jpn J Clin Oncol; 2022 May; 52(5):433-440. PubMed ID: 35079791
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial of alisertib with concurrent fractionated stereotactic re-irradiation for recurrent high grade gliomas.
Song A; Andrews DW; Werner-Wasik M; Kim L; Glass J; Bar-Ad V; Evans JJ; Farrell CJ; Judy KD; Daskalakis C; Zhan T; Shi W
Radiother Oncol; 2019 Mar; 132():135-141. PubMed ID: 30825962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]